THE SIGNAL

George Borba Jr. owns 7,830,941 shares of CVB Financial and just bought 48,894 more at $20.45, writing a $999,985 check on May 22, 2026.

Sit with that for a moment. A director already holding nearly 8 million shares of a regional bank, in the current environment, adds another million dollars. He has more visibility into CVB's loan book than any analyst covering the name. He reviews the actual criticized assets, the real deposit flow data, the examiner feedback. And his conclusion, expressed in cold hard dollars, is that the market has mispriced this bank.

That alone would be a signal worth reading. But Borba is not reading alone.

On the same week, Ernest Rady, the founder and Executive Chairman of American Assets Trust with 13,393,106 shares, added 10,000 more at $22.67. Dustin Norris at NexPoint Diversified Real Estate Trust bought 53,663 shares at $4.90, pushing his total toward 950,000 shares. Eric Oliver, a 10% holder in Cross Timbers Royalty Trust, purchased 18,902 shares at $10.87. The entity under common control at Dorchester Minerals acquired 7,500 more units at $28.30. James Dahl, approaching 1 million shares in AMREP, added 5,000 more at $24.50.

Six insiders across regional banking, office and retail REITs, royalty trusts, and land development all deployed capital in the same short window. This is a cluster, and clusters speak louder than any single trade.

THE INTERPRETATION

What does a bank director with 7.8 million shares see that justifies buying more?

Borba sees the actual loan tape. He knows whether commercial real estate credits are holding, whether deposit costs are stabilizing, whether the criticized-assets list is shrinking or growing. The market has been pricing regional banks with a generalized fear haircut since the 2023 stress events, treating every mid-sized institution as a potential SVB. Borba's buy is a direct rebuttal to that generalization. His message: CVB's specific loan quality, capital ratios, and funding structure are not what the market's fear narrative implies.

Rady at American Assets Trust carries the same logic into the REIT space.

As founder and Executive Chairman, Rady knows every major tenant relationship, every lease renewal negotiation, every refinancing conversation his team has had with lenders. The office-doom narrative has compressed REIT valuations across the sector without distinguishing between operators with strong West Coast mixed-use portfolios and those with genuinely impaired assets. Rady adding at $22.67 says he sees that distinction clearly, and sees it in his favor.

The royalty and land buyers are making a cash-flow argument.

Oliver at Cross Timbers and the Dorchester entity buying LP units are insiders with direct line-of-sight into production data and distribution trajectories. Royalty trusts trade almost entirely on investors' assumptions about future commodity output and prices. When a 10% holder adds materially to a position he already holds in size, he is signaling that the market's production decline assumptions are too pessimistic, or that commodity price forecasts embedded in the current yield are too conservative. Dahl at AMREP, approaching 1 million shares in a land development vehicle, is making a similar NAV argument: the acres on the balance sheet are worth more than the stock implies.

The common thread running through all six of these trades is a conviction that fear-driven discounts have overshot.

These are insiders in asset-heavy, yield-sensitive, rate-exposed businesses. They have been on the receiving end of generalized selling pressure driven by macro narratives about credit cycles, cap rate expansion, and refinancing cliffs. And every single one of them is saying, with their own money, that the internal reality of their specific business does not match the external narrative applied to their sector.

THE SECONDARY SIGNALS

The week also produced a separate cluster that deserves its own reading.

Akkaraju Srinivas, a 10% holder and director at Kalaris Therapeutics, purchased 244,300 shares at $4.83, committing $1.18 million and pushing his total stake past 12.9 million shares. A 10% holder in an early-stage biotech is typically a lead investor or scientific co-founder with direct access to clinical trial progress, FDA interaction timelines, and financing optionality. Adding $1.18 million when you already own 12.7 million shares is a sponsor doubling down. The specific trigger could be enrollment progress, interim data signals, or visibility into a partnership conversation. Whatever it is, he has seen enough to increase a position most investors would already consider large enough.

Opaleye Management, a specialist biotech fund with 10% stakes in multiple names, added to both Alpha Cognition and Sol-Gel Technologies in the same week. Opaleye is a professional with deep sector focus, meaning their incremental accumulation is the product of rigorous clinical and regulatory analysis, not momentum. When the same specialist fund is adding across two separate biotech positions simultaneously, they are expressing a view that biotech risk pricing is broadly too severe in their target universe.

Bradley Tilden, former CEO of Alaska Air and current Boeing director, bought 1,370 shares at $218.50. The dollar amount is modest. The informational weight is significant. Tilden understands exactly what airline customers tell Boeing behind closed doors. He knows whether major carriers are pushing back delivery slots or pulling them forward. His buy, coming after extended scrutiny of Boeing's safety and production execution, carries the message that the franchise is recovering with more credibility than the headline cycle suggests.

Frank Porter Stansberry added $346,000 to his MarketWise stake at $17.21, and Michael Doak committed $620,000 to TWFG at $18.65. Both are financial services insiders with direct visibility into subscriber economics and insurance agency cash flows respectively. Both are buying where market skepticism about post-SPAC execution and insurance distribution margins remains elevated.

THE EVIDENCE

The pattern across this entire slate of trades shares a structural feature: insiders in businesses where book value, asset value, or cash-flow yield is directly observable to them are buying where the market applies a discount driven by macro fear rather than company-specific analysis.

For Borba at CVB Financial, the tell is his existing stake size. A director who holds 7.8 million shares is not supplementing a token position. He is one of the largest individual stakeholders in the institution. Adding $1 million to that exposure is an act of concentrated conviction. Regional bank directors who have watched cycles before buy at points where they believe their institution's specific underwriting history and deposit franchise quality insulate it from the worst of what the market fears. CVB's focus on California business banking, its historically conservative underwriting, and its strong deposit franchise are precisely the kinds of idiosyncratic facts that an insider sees and a macro-bearish analyst discounts.

For the REIT and royalty trust insiders, the evidence structure is similar. NexPoint's listed vehicles frequently trade at discounts to NAV in closed-end structures. Insiders at such vehicles buy when they believe NAV is not only real but growing, and when they see corporate actions on the horizon that could narrow the discount. The Dorchester and Cross Timbers operators have the production data in hand. Their buy is a forward-looking statement about distributions.

The Kalaris buy fits a biotech pattern with a strong historical track record as a signal. Academic and institutional research consistently shows that 10% holders increasing large existing positions in small biotechs generate above-average forward returns, particularly in the 6-to-12-month window surrounding major catalysts. The size and concentration of Srinivas's existing position, combined with a fresh $1.18 million commitment, meets the criteria that the insider-signal literature identifies as highest-quality.

THE REALITY CHECK

What are these insiders collectively revealing about the current moment?

The dominant market narrative through mid-2026 has treated rate-sensitive assets as structurally impaired. Regional banks carry the shadow of 2023 stress. Office and retail REITs carry the shadow of remote work and consumer retrenchment. Royalty trusts carry the shadow of commodity price uncertainty. Land developers carry the shadow of a housing market in transition.

The insiders writing checks this week are not arguing that macro risks are zero. They are arguing something more specific and more actionable: that the discount applied to their particular assets has exceeded the actual impairment those assets will experience. Borba has reviewed the loan file. Rady has reviewed the lease renewals. Oliver has reviewed the production curves. Srinivas has reviewed the trial data. Each of them has arrived at the same conclusion by looking at concrete internal information rather than extrapolating from headlines.

For the next 3 to 6 months, the insiders are positioned for a few specific outcomes. Regional bank earnings that demonstrate credit quality holding within manageable ranges. REIT cash flows that continue to cover dividends and begin narrowing the discount to NAV. Royalty trust distributions that exceed the market's conservative assumptions. A biotech catalyst at Kalaris that the current $4.83 share price is not pricing at fair probability.

The market is applying a generalized fear discount to entire categories of assets. The insiders are responding with category-specific knowledge, deploying capital at prices they believe represent a meaningful gap between external perception and internal reality.

That gap is where the signal lives.